secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001628280-25-004637
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted
-------------------------------------------------------------------------

- Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.
- Sarepta collaboration: $825M upfront ($500M cash + $325M equity at $27.25/share, 35% premium), plus $250M over 5 years, up to $10B milestones.
- Plozasiran NDA for familial chylomicronemia syndrome accepted; PDUFA date Nov 18, 2025.
- Phase 3 PALISADE met primary endpoint; plozasiran reduced triglycerides up to 86% and acute pancreatitis.
- Cash & investments $552.9M; company funded into 2028; obesity programs (ARO-INHBE, ARO-ALK7) entering Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828025004637/0001628280-25-004637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828025004637/arwr-20250210.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer